Document is current
Any future updates will be listed below
-
Authors
Gobom, Johan http://orcid.org/0000-0001-6193-6193
Benedet, Andréa L.
Mattsson-Carlgren, Niklas
Montoliu-Gaya, Laia
Schultz, Nina
Ashton, Nicholas J.
Janelidze, Shorena
Servaes, Stijn
Sauer, Mathias
Pascoal, Tharick A.
Karikari, Thomas K.
Lantero-Rodriguez, Juan
Brinkmalm, Gunnar
Zetterberg, Henrik
Hansson, Oskar
Rosa-Neto, Pedro
Blennow, Kaj
-
Funding
Funding for this research was provided by:
Alzheimerfonden (AF-930934, AF-742881, AF-930627, AF-939932)
Stiftelsen för Gamla Tjänarinnor (2021)
Vetenskapsrådet (2018-02532)
H2020 European Research Council (681712)
Swedish State Support for Clinical Research (ALFGBG-720931, ALFGBG-715986)
Alzheimer's Drug Discovery Foundation (201809-2016862, RDAPB-201809-2016615)
Alzheimer's Association (ADSF-21-831376-C, ADSF-21-831381-C, ADSF-21-831377-C)
Olav Thon Stiftelsen (Olav Thon Stiftelsen)
Familjen Erling-Perssons Stiftelse (Familjen Erling-Perssons Stiftelse)
Hjärnfonden (FO2019-0228, FO2017-0243, FO2020-0240, FO2021-0293)
HORIZON EUROPE Marie Sklodowska-Curie Actions (860197)
UK Dementia Research Institute (UK Dementia Research Institute)
Svenska Forskningsrådet Formas (2017-00915, 2016-00906)
EU Joint Programme – Neurodegenerative Disease Research (JPND2019-466-236)
National Institute of Health (1R01AG068398-01)
BrightFocus Foundation (A2020812F)
Parkinsonfonden (1252/20, 1280/20)
Demensförbundet (Demensförbundet)
Aina (Ann) Wallströms and Mary-Ann Sjöbloms Foundation (Aina (Ann) Wallströms and Mary-Ann Sjöbloms Foundation)
Agneta Prytz-Folkes och Gösta Folkes Stiftelse (2020-00124)
Gun och Bertil Stohnes Stiftelse (Gun och Bertil Stohnes Stiftelse)
Anna-Lisa och Bror Björnssons Stiftelse (Anna-Lisa och Bror Björnssons Stiftelse)
Knut och Alice Wallenbergs Stiftelse (2017-0383)
Marianne and Marcus Wallenberg foundation (2015.0125)
Lunds Universitet (Lunds Universitet)
Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse (Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse)
Skånes universitetssjukhus (2020-O000028)
Swedish State Support under the ALF agreement (2018-Projekt0279)
University of Gothenburg
- License Information
-
More Information
Article History
Received: 10 September 2022
Accepted: 25 November 2022
First Online: 12 December 2022
Declarations
:
: Permission to use CSF samples from the Clinical Routine Laboratory at the Sahlgrenska University Hospital, Mölndal, Sweden for method development was granted by the regional ethics committee in Gothenburg (August 11, 2014). The samples consisted of surplus CSF, which was left over from the routine clinical analysis, and were de-identified prior to use in this study to prevent the possibility to connect the samples to an individual.All participants of the TRIAD cohort included in this report provided written informed consent and the cohort studies were approved by REB from Douglas Hospital Research Centre—Montreal – Canada, no. IUSMD-16–60.Ethical permission to use CSF samples from the BioFINDER-2 cohort was given by the Regional Ethical Committee in Lund, Sweden.
: Not applicable.
: HZ has served at scientific advisory boards and/or as a consultant for Alector, Eisai, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies, CogRx and Red Abbey Labs, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program.KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. OH has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Fujirebio, Genentech, Novartis, Roche, and Siemens.
